Comprehensive medication guide to Dextroamphetamine including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$10–$50 copay for generic; Tier 2 on most plans, but prior authorization and quantity limits may apply due to Schedule II status.
Estimated Cash Pricing
$30–$80 for generic IR tablets with GoodRx or SingleCare coupons; brand Zenzedi runs $200–$400+ without discounts.
Medfinder Findability Score
30/100
Summarize with AI
On this page
Dextroamphetamine is a central nervous system (CNS) stimulant approved by the FDA for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. It is the dextro-isomer of amphetamine and is available as a generic medication as well as under brand names including Dexedrine, Zenzedi, and ProCentra.
Dextroamphetamine helps improve focus, attention, and impulse control in patients with ADHD, and reduces excessive daytime sleepiness in patients with narcolepsy. It is available in immediate-release tablets, extended-release capsules, and an oral solution.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Dextroamphetamine works by increasing the release and blocking the reuptake of two key neurotransmitters in the brain: dopamine and norepinephrine. It also has a minor effect on inhibiting monoamine oxidase. By raising the concentration of these neurotransmitters in the synaptic cleft, Dextroamphetamine improves attention, focus, wakefulness, and executive function.
The immediate-release formulation typically begins working within 30–60 minutes and lasts 4–6 hours, while extended-release capsules provide effects for up to 8–12 hours.
Immediate-Release (IR) Tablets
5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg
Extended-Release (ER) Capsules (Spansule)
5 mg, 10 mg, 15 mg
Oral Solution (ProCentra) — solution
5 mg/5 mL
Dextroamphetamine has a findability score of 35 out of 100, meaning it is frequently difficult to find in stock at pharmacies. The ongoing amphetamine shortage — which began in October 2022 — continues to significantly affect supply in 2026. Most experts expect ongoing supply challenges through at least mid-2026, with some manufacturers reporting that recovery is not expected until well into 2026.
While the DEA increased the Aggregate Production Quota for d-amphetamine to 26.5 million grams in October 2025, this increase has proven insufficient to meet growing demand. The FDA estimates that demand grew 6% from 2023 to 2024, and multiple manufacturers continue to report limited availability or complete stock-outs for various dosages. Many pharmacies report intermittent stock-outs, especially for certain strengths and the extended-release formulation.
If your pharmacy is out of stock, Medfinder can help you locate a pharmacy near you that currently has Dextroamphetamine available.
Because Dextroamphetamine is a Schedule II controlled substance, it must be prescribed by a licensed healthcare provider with DEA registration. Common prescribing specialties include:
Telehealth providers can also prescribe Dextroamphetamine, though regulations vary by state. Some states require an in-person visit for initial Schedule II prescriptions.
Yes. Dextroamphetamine is classified as a Schedule II controlled substance by the DEA due to its high potential for abuse and dependence. This means:
The FDA boxed warning notes that misuse of amphetamines may cause sudden death and serious cardiovascular events. Patients should take Dextroamphetamine exactly as prescribed.
Serious side effects that require immediate medical attention include chest pain, shortness of breath, signs of psychosis (hallucinations, paranoia), new or worsening mood/behavioral changes, and numbness or color changes in fingers and toes (Raynaud's phenomenon).
Know what you need? Skip the search.
Adderall (Mixed Amphetamine Salts)
combination of amphetamine and dextroamphetamine salts; available in IR and XR formulations
Vyvanse (Lisdexamfetamine)
a prodrug of Dextroamphetamine with smoother onset and lower abuse potential
Methylphenidate (Ritalin, Concerta)
a different stimulant class; first-line ADHD treatment with multiple formulations
Atomoxetine (Strattera)
a non-stimulant ADHD medication with no abuse potential
Prefer Dextroamphetamine? We can find it.
MAO Inhibitors
moderateContraindicated. Risk of hypertensive crisis. Do not use within 14 days of an MAOI.
Serotonergic Drugs (SSRIs, SNRIs, Triptans)
moderateincreased risk of serotonin syndrome
Tricyclic Antidepressants
moderateenhanced amphetamine effects and increased cardiovascular risk
CYP2D6 Inhibitors
moderatemay increase Dextroamphetamine blood levels
Antacids and Urinary Alkalinizers
moderatemay increase absorption and effects
Vitamin C, Citrus Juice, and Urinary Acidifiers
moderatemay decrease effectiveness
Antihypertensive Agents
moderateDextroamphetamine may reduce their effectiveness
Dextroamphetamine remains an effective and widely prescribed treatment for ADHD and narcolepsy, but the ongoing stimulant shortage makes finding it in stock a real challenge for patients in 2026. With a findability score of just 35 out of 100, many patients are forced to call multiple pharmacies or go without their medication.
If you're struggling to find Dextroamphetamine, Medfinder can help you locate pharmacies with current stock near you — no more endless phone calls. You can also save money using discount cards like GoodRx and SingleCare, which can bring the cash price down to as low as $30–$45 for a 30-day supply of generic IR tablets.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards